Completed PHASE4 INTERVENTIONAL 3-arm NCT04111432

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine

Sponsor: Shaanxi Provincial Center for Disease Control and Prevention

Conditions Hand, Foot and Mouth Disease

Interventions Concomitant administration of EV71vaccine with EPI vaccines EV71 Vaccine only Single injection of EPI vaccine

Updated 5 times since 2019 Last updated: Jul 26, 2021 Started: Jul 26, 2019 Primary completion: Nov 25, 2019 Completion: Mar 25, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hand, Foot and Mouth Disease, this trial is completed. The trial is conducted by Shaanxi Provincial Center for Disease Control and Prevention and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2021 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE4
Nov 2019 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Jul 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shaanxi Provincial Center for Disease Control and Prevention
Sinovac Biotech Co., Ltd

Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ankang, China